Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Role of MRI in the staging of breast cancer patients: does histological type and molecular subtype matter?

2015; Wiley; Volume: 88; Issue: 1055 Linguagem: Inglês

10.1259/bjr.20150458

1748-880X

Almir Galvão Vieira Bitencourt, Nara P. Pereira, Luciana Karla Lira França, Caroline B Silva, Jociana Paludo, Hugo Lamartine Souza Paiva, Luciana Graziano, Camila Souza Guatelli, Juliana Alves de Souza, Elvira Ferreira Marques,

MRI in cancer diagnosis

To assess the role of MRI in the pre-operative staging of patients with different histological types and molecular subtypes of breast cancer, by the assessment of the dimensions of the main tumour and identification of multifocal and/or multicentric disease.The study included 160 females diagnosed with breast cancer who underwent breast MRI for pre-operative staging. The size of the primary tumour evaluated by MRI was compared with the pathology (gold standard) using the Pearson's correlation coefficient (r). The presence of multifocal and/or multicentric disease was also evaluated.The mean age of patients was 52.6 years (range 30-81 years). Correlation between the largest dimension of the main tumour measured by MRI and pathology was worse for non-special type/invasive ductal carcinoma than for other histological types and was better for luminal A and triple-negative than for luminal B and Her-2 molecular subtypes. Multifocal and/or multicentric disease was present in 48 patients (30.0%), and it was more common in breast carcinomas classified as Her-2 molecular subtype. There was no statistically significant difference in the frequency of multifocal and/or multicentric tumours identified only by MRI in relation to histological type or molecular subtype.The results of this retrospective study demonstrated that histological types and molecular subtypes might influence the MRI assessment of breast cancers, especially in the evaluation of tumour size.The real benefit of MRI for treatment planning in patients with breast cancer may be different according to the histological type and molecular subtype.